Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Aytu BioScience (0A8M) Share Price & Analysis

2 Followers

0A8M Stock Chart & Stats

$2.20$0.00(0.00%)
At close: 4:30 PM GMT
$2.5$5$7.5$10Aug 9Dec 9Aug 2Feb 1Aug 1Jan 30
Day’s Range
$2.20 - $2.20
52-Week Range
$2.20 - $2.20
Previous Close
$2.20
Volume
N/A
Average Volume (3M)
0
Market Cap
$19.67M
Enterprise Value
$33.34M
Total Cash (Recent Filing)
$26.31M
Total Debt (Recent Filing)
$18.11M
Price to Earnings (P/E)
―
Beta
0.62
Next Earnings
Nov 16, 2026 (Est.)
EPS Estimate
-0.26
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

EXXUA Adoption Momentum

EXXUA is showing measurable commercial traction through rising revenue, prescriptions, prescriber adoption, and refill activity. If this adoption continues, the product can diversify Aytu’s revenue base, support operating leverage, and create a durable growth engine beyond the legacy portfolio.

Improved Cash Generation And Deleveraging

The shift to positive operating cash flow alongside substantial debt reduction strengthens financial flexibility. Lower interest obligations can preserve more cash for commercialization and reduce balance-sheet strain, although continued execution is needed to establish this improvement as sustainable.

Established ADHD Portfolio Retention

High prescription retention indicates that the ADHD portfolio has established market presence and continuing customer demand. Its contribution of profit and cash with limited promotional spending provides a funding base for EXXUA investment and supports resilience while the newer product scales.

Bears Say

Persistent Unprofitability

A continuing net loss and negative full-year adjusted EBITDA show that the current business has not yet reached sustainable profitability. This limits internally generated funding for growth, increases dependence on operating improvements, and leaves results vulnerable if commercialization spending does not produce sufficient returns.

Volatile And Declining Revenue Base

Revenue volatility and declines in important legacy portfolios make near-term growth less dependable. Even with sequential improvement, weaker ADHD and pediatrics performance can offset EXXUA gains, complicate expense planning, and delay the scale benefits needed to convert solid gross margins into profits.

EXXUA Investment And Ramp Pressure

EXXUA remains early in its launch, and planned commercialization spending is expected to pressure first-half EBITDA and cash flow before productivity improves. Sales representatives require six to nine months to ramp, creating execution risk and extending the period before investment can generate durable returns.

Aytu BioScience News

0A8M FAQ

What was Aytu BioScience’s price range in the past 12 months?
Aytu BioScience lowest share price was $2.20 and its highest was $2.20 in the past 12 months.
What is Aytu BioScience’s market cap?
Aytu BioScience’s market cap is $19.67M.
When is Aytu BioScience’s upcoming earnings report date?
Aytu BioScience’s next earnings report is estimated for Nov 16, 2026 (not yet confirmed), which is in 3 days.
How were Aytu BioScience’s earnings last quarter?
Aytu BioScience released its earnings results on Sep 22, 2026. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.29 by $0.29.
Is Aytu BioScience overvalued?
According to Wall Street analysts Aytu BioScience’s price is currently Undervalued.
Does Aytu BioScience pay dividends?
Aytu BioScience does not currently pay dividends.
What is Aytu BioScience’s EPS estimate?
Aytu BioScience’s EPS estimate is -0.26.
How many shares outstanding does Aytu BioScience have?
Aytu BioScience has 10,868,208 shares outstanding.
What happened to Aytu BioScience’s price movement after its last earnings report?
Aytu BioScience reported an EPS of $0 in its last earnings report, beating expectations of -$0.29. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Aytu BioScience?
Currently, no hedge funds are holding shares in GB:0A8M
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology